Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
36708811 2023 Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. Journal of hepatology Likely relevant The study experimentally tests anti-PD-1 treatment and SPP1 blockade in mouse models of liver cancer and HCC patients, and measures immune cell infiltration. anti-PD-1; SPP1 blockade Mixed hepatocellular carcinoma anti-PD-1 14/36/0; SPP1 blockade 0/0/0 Awaiting curator check
36795805 2023 CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science (New York, N.Y.) Likely relevant The study investigates the role of CD5+ dendritic cells and their interaction with immune checkpoint blockade in vivo, measuring T cell priming and tumor elimination. immune checkpoint blockade Animal melanoma immune checkpoint blockade 0/1/0 Awaiting curator check
36835382 2023 Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. International journal of molecular sciences Likely relevant Evaluates the PD-1/PD-L1 small-molecule inhibitor CBPA in mouse tumor models, measuring cytokine secretion and T cell infiltration. CBPA Animal colon adenocarcinoma and melanoma CBPA 0/0/0 Awaiting curator check
36842157 2023 PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer. Medical oncology (Northwood, London, England) Likely relevant Experimentally tests PD-L1 inhibitors and chemotherapy in vitro and in vivo, measuring T cell-mediated cell killing. PD-L1 inhibitor; chemotherapy Mixed breast cancer PD-L1 inhibitor 0/0/0; chemotherapy 2/0/3 Awaiting curator check
36853831 2023 Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. The Journal of clinical investigation Likely relevant The study tests decitabine and anti-PD-1 in vitro and in tumor models, reporting detailed cellular and molecular immune readouts such as T cell expansion, proliferation, and cytolytic activity. decitabine; anti-PD-1 Mixed tumor models decitabine 100/12/2; anti-PD-1 14/36/0 Awaiting curator check
36914658 2023 Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nature communications Likely relevant Characterizes the effects of polymerase theta inhibition and anti-PD-1 in immunocompetent breast and pancreatic cancer models, measuring immune responses and cGAS/STING activation. polymerase theta inhibitors; anti-PD-1 Animal triple-negative breast cancer and pancreatic ductal adenocarcinoma polymerase theta inhibitors 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
36963400 2023 Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer cell Likely relevant The study tests antibody-mediated IL-8 blockade and CXCR1/2 inhibitors in mouse models and measures effects on immunosuppressive cell infiltration and anti-PD-1 efficacy. anti-PD-1; IL-8 blocking antibody; CXCR1/2 inhibitor Animal glioma anti-PD-1 14/36/0; IL-8 blocking antibody 0/0/0; CXCR1/2 inhibitor 0/0/0 Awaiting curator check
37019619 2023 Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut Likely relevant The study tests anti-PD-L1 and a PPARgamma antagonist in animal models and patient samples, measuring MDSC accumulation and CD8+ T cell conversion. anti-PD-L1; pembrolizumab; selective PPARgamma antagonist Mixed hepatocellular carcinoma anti-PD-L1 0/15/0; pembrolizumab 0/0/16; selective PPARgamma antagonist 0/0/0 Awaiting curator check
37026630 2023 Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study experimentally tests ferroptosis inducers and anti-PD-L1 antibodies in a murine HNSCC model and measures immune-related readouts such as PD-L1 expression and active immune cell profiles. anti-PD-L1 antibody; ferroptosis inducer Animal Head and Neck Squamous Cell Carcinoma anti-PD-L1 antibody 0/1/0; ferroptosis inducer 0/0/0 Awaiting curator check
37027467 2023 Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response. Science advances Likely relevant The study tests the small molecule PIK-93 in combination with anti-PD-L1 antibodies in vitro and in vivo, and measures effects on macrophage PD-L1, cytotoxicity, T cell activation, and TIL recruitment. PIK-93; anti-PD-L1 antibody Mixed non-small cell lung cancer PIK-93 0/0/0; anti-PD-L1 antibody 0/1/0 Awaiting curator check
37028428 2023 Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell Likely relevant The study experimentally tests immune checkpoint inhibitors in combination with probiotics/metabolites in a preclinical melanoma model and measures CD8+ T cell responses. immune checkpoint inhibitor Animal melanoma immune checkpoint inhibitor 0/0/0 Awaiting curator check
37080489 2023 Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The study tests a BRAF inhibitor (vemurafenib) and anti-PD-1 antibody in murine melanoma models, reporting local immunomodulation. vemurafenib; antagonistic programmed cell death protein 1 antibody (aPD-1) Animal melanoma vemurafenib 52/2/7; antagonistic programmed cell death protein 1 antibody (aPD-1) 0/0/0 Awaiting curator check
37106265 2023 An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma. Clinical and experimental medicine Likely relevant Investigates the effects of an HPK1 inhibitor combined with anti-PD-1 immunotherapy on T-cell cytotoxicity and immune marker expression in cell lines and xenograft models. HPK1 inhibitor; anti-PD-1 Mixed non-Hodgkin's lymphoma HPK1 inhibitor 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
37138075 2023 Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature Likely relevant The study experimentally tests PD-L2-RGMb pathway blocking antibodies combined with anti-PD-1/anti-PD-L1 in mice and measures anti-tumor immune responses. anti-PD-1; anti-PD-L1; anti-PD-L2-RGMb pathway blocking antibodies Animal cancer (multiple mouse tumour models) anti-PD-1 14/36/0; anti-PD-L1 0/15/0; anti-PD-L2-RGMb pathway blocking antibodies 0/0/0 Awaiting curator check
37192546 2023 Induction of Tumor Ferroptosis-Dependent Immunity via an Injectable Attractive Pickering Emulsion Gel. Advanced materials (Deerfield Beach, Fla.) Likely relevant The study experimentally tests RSL-3 and PD-1 antibody in tumour-bearing animals and reports measured effects on immune cell accumulation and antitumor immune response. (1S, 3R)-RSL-3; programmed death-1 (PD-1) antibody Animal hepatocellular carcinoma and pancreatic cancer (1S, 3R)-RSL-3 0/0/0; programmed death-1 (PD-1) antibody 0/0/0 Awaiting curator check
37193754 2023 Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1. Acta pharmacologica Sinica Likely relevant Tests platinum compounds in immunocompetent mice with colorectal cancer xenografts and measures tumor-infiltrating T cells. bis(benzonitrile) dichloroplatinum (II); cisplatin Animal colorectal cancer bis(benzonitrile) dichloroplatinum (II) 0/0/0; cisplatin 18/3/11 Awaiting curator check
37247886 2023 Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes. Anticancer research Likely relevant Experimentally tests anti-PD-1/PD-L1 antibodies on the THP-1 cell line and measures apoptosis, adhesion molecule expression, and cytokine release. Nivolumab; Pembrolizumab; Atezolizumab; Durvalumab Cell line monocytic leukemia Nivolumab 1/2/4; Pembrolizumab 0/0/16; Atezolizumab 0/0/4; Durvalumab 0/0/2 Awaiting curator check
37311042 2023 PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells. Cancer research Likely relevant Tests anti-PD-1, TLR agonists, and anti-TGFβ antibody in a Pten-null LUSC mouse model and measures immune readouts like Treg infiltration and PD-L1/PD-L2 levels. anti-programmed cell death protein 1 (anti-PD-1); TLR agonists; anti-TGFβ antibody Animal Non-Small Cell Lung Cancer anti-programmed cell death protein 1 (anti-PD-1) 0/0/0; TLR agonists 0/0/0; anti-TGFβ antibody 0/0/0 Awaiting curator check
37344596 2023 Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature Likely relevant The study tests the response to anti-PD-1 immune checkpoint blockade therapy in mice and patients with bladder cancer with loss of the Y chromosome, measuring CD8+ T cell exhaustion. anti-PD-1 Mixed bladder cancer anti-PD-1 14/36/0 Awaiting curator check
37357254 2023 TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal transduction and targeted therapy Likely relevant Evaluates PD-L1 and TBK1 inhibitors in mice, measuring changes in T cell activation and tumor progression. PD-L1 inhibitor; TBK1 inhibitor; CTLA4 Animal gastric cancer PD-L1 inhibitor 0/0/0; TBK1 inhibitor 0/0/0; CTLA4 0/0/0 Awaiting curator check
37429863 2023 ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade. Nature communications Likely relevant The study experimentally tests cisplatin and ACY738 in mouse tumor models and measures their effects on cytotoxic T cell infiltration and STING signaling. cisplatin; PD-L1 blockade; ACY738 Animal tumor model cisplatin 18/3/11; PD-L1 blockade 0/4/0; ACY738 0/0/0 Awaiting curator check
37430270 2023 Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer. Cell communication and signaling : CCS Likely relevant Evaluates the combination of PD-1 inhibitor and Shenmai injection in mouse models and in vitro, reporting comprehensive immune readouts on NK cells and T cells. PD-1 inhibitor; Shenmai injection Mixed Non-Small Cell Lung Cancer PD-1 inhibitor 0/0/0; Shenmai injection 0/0/0 Awaiting curator check
37474523 2023 Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nature communications Likely relevant The study tests anti-GDF-15 neutralization and PD-1 blockade in murine tumor models and patient samples, measuring T cell trafficking and extravasation. anti-PD-1; anti-GDF-15 antibody Mixed melanoma anti-PD-1 14/36/0; anti-GDF-15 antibody 0/0/0 Awaiting curator check
37515321 2023 Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Molecular therapy : the journal of the American Society of Gene Therapy Likely relevant The study experimentally tests LRRK2 inhibitors, anti-PD-L1, and adenosylcobalamin in cell lines and mice, measuring effects on CD8+ T cells and immune responses. anti-PD-L1; adenosylcobalamin Mixed pancreatic ductal adenocarcinoma anti-PD-L1 0/15/0; adenosylcobalamin 0/0/0 Awaiting curator check
37543621 2023 Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nature communications Likely relevant Tests combined TGFbeta and PD-L1 blockade in a mouse tumor model, measuring CD8 T cell compartments and IFNgamma signaling. anti-PD-L1; anti-TGFbeta Animal breast cancer anti-PD-L1 0/15/0; anti-TGFbeta 0/0/0 Awaiting curator check
← Previous Page 10 of 15 Next →